JP2016536340A - コラーゲンおよびエラスチン刺激化合物およびこのような化合物を含む局所組成物 - Google Patents
コラーゲンおよびエラスチン刺激化合物およびこのような化合物を含む局所組成物 Download PDFInfo
- Publication number
- JP2016536340A JP2016536340A JP2016542314A JP2016542314A JP2016536340A JP 2016536340 A JP2016536340 A JP 2016536340A JP 2016542314 A JP2016542314 A JP 2016542314A JP 2016542314 A JP2016542314 A JP 2016542314A JP 2016536340 A JP2016536340 A JP 2016536340A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- skin
- compound
- collagen
- hair
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 107
- 239000000203 mixture Substances 0.000 title claims abstract description 66
- 102000008186 Collagen Human genes 0.000 title claims description 78
- 108010035532 Collagen Proteins 0.000 title claims description 78
- 229920001436 collagen Polymers 0.000 title claims description 77
- 102000016942 Elastin Human genes 0.000 title claims description 30
- 108010014258 Elastin Proteins 0.000 title claims description 30
- 229920002549 elastin Polymers 0.000 title claims description 30
- 230000000699 topical effect Effects 0.000 title claims description 23
- 230000004936 stimulating effect Effects 0.000 title description 6
- 239000002537 cosmetic Substances 0.000 claims abstract description 22
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 12
- 210000004209 hair Anatomy 0.000 claims description 47
- 230000003779 hair growth Effects 0.000 claims description 39
- 239000006071 cream Substances 0.000 claims description 27
- 201000004384 Alopecia Diseases 0.000 claims description 25
- 230000008439 repair process Effects 0.000 claims description 16
- 231100000360 alopecia Toxicity 0.000 claims description 9
- 230000006378 damage Effects 0.000 claims description 9
- 208000009043 Chemical Burns Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- -1 barrier repair Substances 0.000 claims description 7
- 230000003716 rejuvenation Effects 0.000 claims description 7
- 230000003712 anti-aging effect Effects 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 4
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 claims description 4
- 239000003995 emulsifying agent Substances 0.000 claims description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 4
- 230000036562 nail growth Effects 0.000 claims description 4
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 208000010195 Onychomycosis Diseases 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- BITHHVVYSMSWAG-KTKRTIGZSA-N (11Z)-icos-11-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCC(O)=O BITHHVVYSMSWAG-KTKRTIGZSA-N 0.000 claims description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
- ATNNLHXCRAAGJS-QZQOTICOSA-N (e)-docos-2-enoic acid Chemical compound CCCCCCCCCCCCCCCCCCC\C=C\C(O)=O ATNNLHXCRAAGJS-QZQOTICOSA-N 0.000 claims description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
- 230000033616 DNA repair Effects 0.000 claims description 2
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 claims description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000005642 Oleic acid Substances 0.000 claims description 2
- 235000021314 Palmitic acid Nutrition 0.000 claims description 2
- 235000021319 Palmitoleic acid Nutrition 0.000 claims description 2
- 108010050808 Procollagen Proteins 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 230000004888 barrier function Effects 0.000 claims description 2
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 claims description 2
- 238000004040 coloring Methods 0.000 claims description 2
- BITHHVVYSMSWAG-UHFFFAOYSA-N eicosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCC(O)=O BITHHVVYSMSWAG-UHFFFAOYSA-N 0.000 claims description 2
- 229940108623 eicosenoic acid Drugs 0.000 claims description 2
- 239000003974 emollient agent Substances 0.000 claims description 2
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 claims description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 2
- 235000020778 linoleic acid Nutrition 0.000 claims description 2
- 230000003020 moisturizing effect Effects 0.000 claims description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- 206010040882 skin lesion Diseases 0.000 claims description 2
- 231100000444 skin lesion Toxicity 0.000 claims description 2
- 230000001153 anti-wrinkle effect Effects 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 abstract description 10
- 210000003491 skin Anatomy 0.000 description 87
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 50
- 230000000694 effects Effects 0.000 description 39
- 238000011282 treatment Methods 0.000 description 36
- 239000000047 product Substances 0.000 description 33
- 238000005259 measurement Methods 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 20
- 150000001336 alkenes Chemical class 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- 230000003676 hair loss Effects 0.000 description 14
- 208000024963 hair loss Diseases 0.000 description 14
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- 239000002199 base oil Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000004006 olive oil Substances 0.000 description 9
- 235000008390 olive oil Nutrition 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- UOYZDQLVFKVZIO-UHFFFAOYSA-N CC(C)C12CC(=CC(C)=C1)C2(C)C Chemical compound CC(C)C12CC(=CC(C)=C1)C2(C)C UOYZDQLVFKVZIO-UHFFFAOYSA-N 0.000 description 8
- 230000003796 beauty Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 238000011084 recovery Methods 0.000 description 8
- 238000002803 maceration Methods 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 238000002604 ultrasonography Methods 0.000 description 7
- 238000000540 analysis of variance Methods 0.000 description 6
- 210000004207 dermis Anatomy 0.000 description 6
- 230000037308 hair color Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 238000004949 mass spectrometry Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 230000037394 skin elasticity Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 230000032683 aging Effects 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 210000001061 forehead Anatomy 0.000 description 5
- 229930014626 natural product Natural products 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 210000004761 scalp Anatomy 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000001134 F-test Methods 0.000 description 4
- 241000221095 Simmondsia Species 0.000 description 4
- 235000004433 Simmondsia californica Nutrition 0.000 description 4
- 150000001335 aliphatic alkanes Chemical class 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000000356 contaminant Substances 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 230000001815 facial effect Effects 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 229940119170 jojoba wax Drugs 0.000 description 4
- 238000000329 molecular dynamics simulation Methods 0.000 description 4
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 4
- 231100000075 skin burn Toxicity 0.000 description 4
- KNKRKFALVUDBJE-UHFFFAOYSA-N 1,2-dichloropropane Chemical compound CC(Cl)CCl KNKRKFALVUDBJE-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- SIVKZPBURVINMX-UHFFFAOYSA-N bicyclo[3.3.1]non-4-ene Chemical compound C1CC=C2CCCC1C2 SIVKZPBURVINMX-UHFFFAOYSA-N 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000000720 eyelash Anatomy 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- DQYBRTASHMYDJG-UHFFFAOYSA-N Bisindolylmaleimide Chemical compound C1=CC=C2C(C=3C(=O)NC(C=3C=3C4=CC=CC=C4NC=3)=O)=CNC2=C1 DQYBRTASHMYDJG-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical group C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 238000003547 Friedel-Crafts alkylation reaction Methods 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 206010051246 Photodermatosis Diseases 0.000 description 2
- 208000028990 Skin injury Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- BEWYHVAWEKZDPP-UHFFFAOYSA-N bornane Chemical compound C1CC2(C)CCC1C2(C)C BEWYHVAWEKZDPP-UHFFFAOYSA-N 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- CRPUJAZIXJMDBK-UHFFFAOYSA-N camphene Chemical compound C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000003660 hair regeneration Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical compound CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 description 2
- 230000008845 photoaging Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000012925 reference material Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000003813 thin hair Effects 0.000 description 2
- 210000003371 toe Anatomy 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- 241001440684 Abrus pulchellus subsp. tenuiflorus Species 0.000 description 1
- 241000349728 Archidendron Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010026206 Conalbumin Proteins 0.000 description 1
- XETQTCAMTVHYPO-UHFFFAOYSA-N Isocamphan von ungewisser Konfiguration Natural products C1CC2C(C)(C)C(C)C1C2 XETQTCAMTVHYPO-UHFFFAOYSA-N 0.000 description 1
- 241000123868 Justicia ventricosa Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241001079660 Phanes Species 0.000 description 1
- PXRCIOIWVGAZEP-UHFFFAOYSA-N Primaeres Camphenhydrat Natural products C1CC2C(O)(C)C(C)(C)C1C2 PXRCIOIWVGAZEP-UHFFFAOYSA-N 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 101100213603 Schizosaccharomyces pombe (strain 972 / ATCC 24843) hrf1 gene Proteins 0.000 description 1
- 241001091465 Sempervivum Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 150000003924 bisindolylmaleimides Chemical class 0.000 description 1
- 229930006742 bornane Natural products 0.000 description 1
- 229930006739 camphene Natural products 0.000 description 1
- ZYPYEBYNXWUCEA-UHFFFAOYSA-N camphenilone Natural products C1CC2C(=O)C(C)(C)C1C2 ZYPYEBYNXWUCEA-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 150000001925 cycloalkenes Chemical class 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 238000010252 digital analysis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 238000012617 force field calculation Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 230000003646 hair health Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012900 molecular simulation Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000003170 nutritional factors Nutrition 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 150000003048 pinane derivatives Chemical class 0.000 description 1
- XOKSLPVRUOBDEW-UHFFFAOYSA-N pinane group Chemical group C12C(CCC(C1(C)C)C2)C XOKSLPVRUOBDEW-UHFFFAOYSA-N 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 150000003413 spiro compounds Chemical class 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 230000003335 steric effect Effects 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 201000005882 tinea unguium Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000701 toxic element Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000037331 wrinkle reduction Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C13/00—Cyclic hydrocarbons containing rings other than, or in addition to, six-membered aromatic rings
- C07C13/28—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof
- C07C13/32—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings
- C07C13/39—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with a bicyclo ring system containing seven carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q3/00—Manicure or pedicure preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cosmetics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
を有する二環式化合物と、を含む美容および治療組成物に関する。
を有する、化学的化合物、医薬化合物または医薬的に許容可能なその塩および美容化合物に関する。
を有する化合物を含む局所的美容/医薬組成物(例えばクリーム)にも関する。
0.001重量%から0.01重量%、0.001重量%から0.02重量%,0.001重量%から0.03重量%、0.001重量%から0.04重量%、0.001重量%から0.05重量%、0.001重量%から0.06重量%、0.001重量%から0.07重量%、0.001重量%から0.08重量%、0.001重量%から0.09重量%、0.001重量%から0.1重量%、0.001重量%から0.2重量%、0.001重量%から0.3重量%、0.001重量%から0.4重量%、0.001重量%から0.5重量%、0.001重量%から0.6重量%、0.001重量%から0.7重量%、0.001重量%から0.8重量%、0.001重量%から0.9重量%、0.001重量%から1重量%、0.001重量%から2重量%、0.001重量%から3重量%、0.001重量%から4重量%、0.001重量%から5重量%、0.001重量%から6重量%、0.001重量%から7重量%、0.001重量%から8重量%、0.001重量%から9重量%、0.001重量%から10重量%、0.001重量%から11重量%、0.001重量%から12重量%、0.001重量%から13重量%、0.001重量%から13重量%、0.001重量%から14重量%、0.001重量%から15重量%、0.001重量%から16重量%、0.001重量%から17重量%、0.001重量%から18重量%、0.001重量%から19重量%、0.001重量%から20重量%の式(I)の有効な化合物。
−生成物A:式(I)の化合物:0.1重量%から99.9重量%
−許容可能なビヒクル(基油=例えばホホバ油またはオリーブ油):0から99.9重量%
−水:0から99.9重量%
−乳化剤(tefose(登録商標)2000):0から50重量%
−プロピレングリコール:0から99.9重量%。
−生成物A:式(I)の化合物(100倍希釈):13重量%
−許容可能なビヒクル(基油=例えばホホバ油またはオリーブ油):7重量%
−水:57重量%
−乳化剤(tefose(登録商標)2000):3重量%
−プロピレングリコール:20重量%。
当業者は、次の情報により、本発明の化合物を製造する方法が分かる。
本発明の化合物(すなわち式(I)のJR101s化合物)の化学的特徴評価を行うために、ヘキサンおよびトルエンなどの有機疎水性溶媒を用いて質量分析を行った。また、質量分析研究において溶媒を参照物質として使用した。
インデックス3(3)は1,2−ジクロロプロパンに対応する。
インデックス5(5)はトルエンに対応する。
インデックス6(6)およびインデックス7(7)は反応の生成物に対応する。
単位(最後のカラム)は各反応物および生成物の分子量の%に対応する。
Sempervivumという名称の医療美容会社(medical esthetics company)により行われた臨床試験によって本発明による美容組成物の効果が評価された。
分析的理由のために、参加者を4つの異なる年齢群に分けた。第一の群では、参加者は55歳より若く;第二の群では55歳から64歳の参加者が含まれた。第三の群では、参加者は65歳から74歳の間であり、第四の群では参加者は75歳超であった。
表2において、異なる測定領域に対して、試験の開始時および1、2、3および4カ月後の平均コラーゲンスコア(および標準偏差)を与える。
「Mes」は「平均弾力性スコア」を表す。
「SD」は「標準偏差」を表す。
表3において、様々な測定領域に対する試験開始時および1カ月および2カ月後の平均弾力性スコアおよび標準偏差を与える。
「Mes」は「平均弾力性スコア」を表す。
「SD」は「標準偏差」を表す。
(E)はヤング係数である。(VE)は粘弾性である。
4カ月の試験において、皮膚におけるコラーゲンおよびエラスチンレベルを、これらのレベルに対する局所組成物(クリーム)中の本発明の化合物(JR101)の有効性と一緒に調べた。結果から、顔面の異なる数カ所の皮膚におけるコラーゲンおよびエラスチンレベルを刺激することにおいて、局所組成物が非常に有効であることが示唆される。皮膚における効果は、少なくとも最初の2カ月間にわたって持続すると思われ、全ての様々な年齢群に対して観察されると思われる。2カ月後のコラーゲンレベルにおける効果は、8強度ポイントのオーダーであり、ベースラインと比較してコラーゲンが30%増加している。4カ月後、増加は、最大15ポイントであるかまたはベースラインと比較してコラーゲンが55%増加した。2カ月後のエラスチンレベルに対する効果は、0.7弾力性ポイントのオーダーであり、ベースラインと比較してエラスチンが25%増加している。4カ月後、ベースラインと比較してエラスチンレベルが28%上昇した。
20名のボランティア(8名の女性)がこの試験に参加した。参加者の平均年齢は54歳(SD=11歳)であった。参加者は毛髪移植歴がなく、摂食および睡眠パターンは正常であった。
菲薄爪であり、長期間持続する爪真菌疾患がある女性が、1カ月間にわたり1日2回足を処置した。爪は、より強く、よりつややかになり、爪先の真菌は徐々に消失した。1カ月後、爪先には完全に真菌がなくなった。
クリーム調製物(美容および治療):
次のプロトコールに従い、パイロット生産用の活性成分/生成物としてJR101s入りのクリームを作製した:油性調製物:
希釈1/100の例:40mL(JR101s 不純)+および4リットルの油(例えば:ホホバまたはオリーブ油)=生成物A
表5:
[1] Ulf Peters: Thesis: Studies Towards Anti-Bredt Ring Systems of Natural Products, the University of Tennessee, Knoxville, August 2002
[2] Gert Kobrich: Bredt Compounds and the Bredt Rule. Angew. Chem. Internat. Edit 1973
[3] A study of the effects of Strain on the Structure and Reactivity of Bridgehead Olefins: Lease, T.G., et al J Am Chem Soc 1993
[4] Wilhelm F. Maer and Paul von Rague Schleyer: Evaluation and Prediction of the stability of Bridgehead Olefins. J. Am Chem Soc 1981 , 103, 1891-1900
[5] Stephen L. Mayo et al: DREIDING: A Generic Force Field for Molecular Simulation. J. Phys Chem. 1990, 94, 8897-8909.
[6] Bartlett S, Bolt A, Ironmonger A, Joce C, Nelson A, Woodhall T. Configurational stability of bisindolylmaleimide cyclophanes: from conformers to the first configurationally stable, atropisomeric bisindolylmaleimides. Chemistry. 2005 Oct 21 ;1 1 (21 ):6277-85.
[7] Li C1 , Choi P. Molecular dynamics study of the molecular weight dependence of surface tensions of normal alkanes and methyl methacrylate oligomers. J Phys Chem B. 2006 Apr 6;110(13):6864-70.Curcio, N.M. & Parish, L.C. (2009). Injectable fillers: An American perspective. Giomale Italiano di dermatologia venereologia, 3, 271- 279.
DermaLab Combo (2010). Cortex Technology, Denmark.
De Rigal, J., Escoffier, C, Querleux, B., Faivre, B, Agache, P, & Leveque, J.J. (1989). Assessment of aging of the human skin by In vivo ultrasonic imaging. J Invest Dermatol. 93, 621 -625.
Claims (14)
- 式(I)
を有する化合物。 - 薬剤としての使用のための、式(I):
を有する化合物
または医薬的に許容可能なその塩。 - 熱傷および/または化学火傷または熱湯傷および/または脱毛症からヒト皮膚を予防するかまたはこれを処置することにおける使用のための、式(I):
を有する化合物
または医薬的に許容可能なその塩。 - 少なくともある許容可能なビヒクルと、有効量の式(I)
の化合物と、を含む組成物。 - 0.001重量%から99.9重量%、好ましくは0.1重量%から99.9重量%、より好ましくは0.1重量%から50重量%、最も好ましくは0.1重量%から20重量%、さらにより好ましくは0.1%から15%の式(I)の有効な化合物を含有する、請求項4に記載の組成物。
- 前記許容可能なビヒクルが、パルミチン酸、パルミトレイン酸、エルカ酸、エイコセン酸、ドコセン酸、オレイン酸およびリノール酸からなる群から選択される、請求項4または5の何れかに記載の組成物。
- 前記式(I)の化合物が、少なくとも以下の老化防止成分のカテゴリー:DNA修復、細胞修復、抗皺、抗発赤、抗着色、抗UV損傷、抗酸化、バリア修復、皮膚軟化/保湿特性、プロコラーゲン、抗異常皮膚病変、抗爪真菌およびUV損傷改善またはそれらの組み合わせ:の活性形態に含まれると定義される、ヒト皮膚、毛髪および爪への適用のための局所老化防止化合物である、請求項4から6の何れかに記載の組成物。
- −式(I)の化合物:0.1重量%から99.9重量%と、
−許容可能なビヒクル:0重量%から99.9重量%と、
−水:0重量%から99.9重量%と、
−乳化剤:0重量%から50重量%と、
−プロピレングリコール:0重量%から99.9重量%と、
を含む、請求項4から7の何れかに記載の組成物。 - ヒト皮膚においてコラーゲンおよびエラスチンのレベルを上昇させるための、請求項4から8の何れかに記載の組成物の使用。
- 毛髪または爪の成長のための、請求項4から8の何れかに記載の組成物の使用。
- 美容的な皮膚若返りおよび修復のための、請求項4から8の何れかに記載の組成物の使用。
- 美容的な爪若返りおよび爪修復のための、請求項4から8の何れかに記載の組成物の使用。
- 請求項4から8の何れかに記載の組成物を含むクリーム。
- 美容または治療用途用である、請求項13に記載のクリーム。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
LU92277A LU92277B1 (fr) | 2013-09-11 | 2013-09-11 | Composé cosmétique |
LU92277 | 2013-09-11 | ||
PCT/EP2014/069424 WO2015036498A1 (en) | 2013-09-11 | 2014-09-11 | Collagen and elastin stimulating compound and topical compositions comprising such compound |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016536340A true JP2016536340A (ja) | 2016-11-24 |
JP6693878B2 JP6693878B2 (ja) | 2020-05-13 |
Family
ID=49253380
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016542314A Active JP6693878B2 (ja) | 2013-09-11 | 2014-09-11 | コラーゲンおよびエラスチン刺激化合物およびこのような化合物を含む局所組成物 |
Country Status (33)
Country | Link |
---|---|
US (1) | US10426741B2 (ja) |
EP (1) | EP3044195B1 (ja) |
JP (1) | JP6693878B2 (ja) |
KR (1) | KR102080966B1 (ja) |
CN (1) | CN105683138A (ja) |
AU (1) | AU2014320342B2 (ja) |
BR (1) | BR112016005532B1 (ja) |
CA (1) | CA2924170C (ja) |
CL (1) | CL2016000561A1 (ja) |
CY (1) | CY1124142T1 (ja) |
DK (1) | DK3044195T3 (ja) |
EA (1) | EA033121B1 (ja) |
ES (1) | ES2869898T3 (ja) |
HR (1) | HRP20210717T1 (ja) |
HU (1) | HUE054445T2 (ja) |
IL (1) | IL244543B (ja) |
LT (1) | LT3044195T (ja) |
LU (1) | LU92277B1 (ja) |
MA (1) | MA38905B1 (ja) |
MX (1) | MX2016003257A (ja) |
MY (1) | MY173634A (ja) |
NZ (1) | NZ717696A (ja) |
PE (1) | PE20170293A1 (ja) |
PH (1) | PH12016500460B1 (ja) |
PL (1) | PL3044195T3 (ja) |
PT (1) | PT3044195T (ja) |
RS (1) | RS61792B1 (ja) |
SG (1) | SG11201601729PA (ja) |
SI (1) | SI3044195T1 (ja) |
TN (1) | TN2016000097A1 (ja) |
UA (1) | UA119752C2 (ja) |
WO (1) | WO2015036498A1 (ja) |
ZA (1) | ZA201602266B (ja) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE285092C (ja) | ||||
DD285092A5 (de) * | 1989-06-22 | 1990-12-05 | Veb Chemische Werke Buna,Dd | Verfahren zur erhoehung der selektivitaet der friedel-crafts-alkylierung von aromaten mit 1,2-dihalogenalkanen |
ZA969617B (en) | 1995-11-15 | 1998-02-19 | Picower Inst Med Res | Method and agents for inhibiting protein aging. |
WO2001087292A2 (en) | 2000-05-15 | 2001-11-22 | Canadian Inovatech, Inc. | Compositions for the preservation of collagen and elastin |
US10195136B2 (en) | 2011-08-24 | 2019-02-05 | Avon Products, Inc. | Collagen and elastin stimulating compositions and uses thereof |
US10434049B2 (en) * | 2013-09-11 | 2019-10-08 | Joventis, S.A. | Methods of producing compounds that stimulate hair regrowth, topical formulations, and methods of use |
-
2013
- 2013-09-11 LU LU92277A patent/LU92277B1/xx active
-
2014
- 2014-09-11 EA EA201690527A patent/EA033121B1/ru unknown
- 2014-09-11 AU AU2014320342A patent/AU2014320342B2/en active Active
- 2014-09-11 MY MYPI2016700791A patent/MY173634A/en unknown
- 2014-09-11 LT LTEP14761894.6T patent/LT3044195T/lt unknown
- 2014-09-11 TN TN2016000097A patent/TN2016000097A1/en unknown
- 2014-09-11 PE PE2016000360A patent/PE20170293A1/es active IP Right Grant
- 2014-09-11 PL PL14761894T patent/PL3044195T3/pl unknown
- 2014-09-11 US US14/917,941 patent/US10426741B2/en active Active
- 2014-09-11 CN CN201480059555.1A patent/CN105683138A/zh active Pending
- 2014-09-11 ES ES14761894T patent/ES2869898T3/es active Active
- 2014-09-11 JP JP2016542314A patent/JP6693878B2/ja active Active
- 2014-09-11 HU HUE14761894A patent/HUE054445T2/hu unknown
- 2014-09-11 DK DK14761894.6T patent/DK3044195T3/da active
- 2014-09-11 MA MA38905A patent/MA38905B1/fr unknown
- 2014-09-11 SG SG11201601729PA patent/SG11201601729PA/en unknown
- 2014-09-11 CA CA2924170A patent/CA2924170C/en active Active
- 2014-09-11 WO PCT/EP2014/069424 patent/WO2015036498A1/en active Application Filing
- 2014-09-11 EP EP14761894.6A patent/EP3044195B1/en active Active
- 2014-09-11 NZ NZ717696A patent/NZ717696A/en unknown
- 2014-09-11 MX MX2016003257A patent/MX2016003257A/es unknown
- 2014-09-11 SI SI201431816T patent/SI3044195T1/sl unknown
- 2014-09-11 KR KR1020167009141A patent/KR102080966B1/ko active IP Right Grant
- 2014-09-11 PT PT147618946T patent/PT3044195T/pt unknown
- 2014-09-11 BR BR112016005532-2A patent/BR112016005532B1/pt active IP Right Grant
- 2014-09-11 UA UAA201603809A patent/UA119752C2/uk unknown
- 2014-09-11 RS RS20210526A patent/RS61792B1/sr unknown
-
2016
- 2016-03-09 PH PH12016500460A patent/PH12016500460B1/en unknown
- 2016-03-10 CL CL2016000561A patent/CL2016000561A1/es unknown
- 2016-03-10 IL IL24454316A patent/IL244543B/en active IP Right Grant
- 2016-04-04 ZA ZA2016/02266A patent/ZA201602266B/en unknown
-
2021
- 2021-04-14 CY CY20211100326T patent/CY1124142T1/el unknown
- 2021-05-07 HR HRP20210717TT patent/HRP20210717T1/hr unknown
Non-Patent Citations (2)
Title |
---|
DEREK L. RANSLEY: "The Alkylation of Benzene with 1,2-Dichloroalkanes", THE JOURNAL OF ORGANIC CHEMISTRY, vol. 31, no. 11, JPN6018016691, 1 November 1966 (1966-11-01), pages 3595 - 3599, XP055115841, DOI: doi:10.1021/jo01349a029 * |
SHINJI MASUDA; MASAHITO SEGI; TADASHI NAKAJIMA; SOHEI SUGA: "THE PARTICIPATION EFFECT OF HALOGEN ATOMS IN STEREOSPECIFIC FRIEDEL-CRAFTS ALKYLATIONS", JOURNAL OF THE CHEMICAL SOCIETY; CHEMICAL COMMUNICATIONS, vol. NR:3, JPN5016009914, 1 January 1980 (1980-01-01), pages PAGE(S):86 - 87 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101180030B (zh) | 化妆品及皱纹改善剂 | |
US11318077B2 (en) | Retinaldehyde containing compositions and methods of use | |
Raikou et al. | The efficacy study of the combination of tripeptide‐10‐citrulline and acetyl hexapeptide‐3. A prospective, randomized controlled study | |
MX2013004214A (es) | Uso de inhibidores de monoamina oxidasa para mejorar la biologia epitelial. | |
KR20200050944A (ko) | 미용 조성물 및 사용 방법 | |
WO2012049697A1 (en) | Preparation for antiwrinkle treatment based on caffeine micro - patches beta-glucan polysaccarides | |
JP6693878B2 (ja) | コラーゲンおよびエラスチン刺激化合物およびこのような化合物を含む局所組成物 | |
US20240074964A1 (en) | A nutraceuticals formulation with an enhanced organoleptic properties used for skin care | |
LODéN et al. | Changes in European legislation make it timely to introduce a transparent market surveillance system for cosmetics | |
JP5952261B2 (ja) | 化粧用組成物における機能的なチラコイドを含む光合成細胞抽出物の使用 | |
EP2253304B1 (en) | Nifedipine-based compositions for anti-wrinkle treatments | |
EA019383B1 (ru) | Косметическое средство, предназначенное для ухода за кожей лица и тела (варианты) | |
US20220331223A1 (en) | Hair treatment compositions and methods of use | |
US20230301890A1 (en) | Compositions comprising urolithins | |
Matthews‑Brzozowska et al. | CGF Harmony facial skin revitalization for a 40+ patient | |
WO2017095887A1 (en) | Topical skin compositions having proteins and methods of use | |
RU2568589C1 (ru) | Способ коррекции эстетических и возрастных проблем кожи | |
EP4255369A1 (en) | Peeling formulation | |
JP4456918B2 (ja) | シワ改善剤 | |
Adikrishnan et al. | Murugan S, Mahalakshmi V, Anandan S, Sudha R Department of Dermatology, Sri Ramachandra University, Chennai, India Introduction: Kerion is an inflammatory type of tinea capitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170906 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180502 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180516 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190214 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190510 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190711 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190814 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191204 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200228 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200319 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200416 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6693878 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |